康臣药业集团有限公司（股票代码：01681）于2026年6月15日发布公告，披露其在香港联合交易所场内回购股份的最新情况。本次回购涉及普通股合计168,000股，约占回购前公司已发行股本（不包括库藏股）总数840,291,111股的0.02%。每股回购价格介乎港币13.37元至13.56元，总成交金额为港币2,263,900元，折合约226.39万港元。
本次股份购回完成后，公司已发行股份总数减至840,123,111股，库藏股合计增至1,424,000股。此前，公司已于2026年5月26日获得股东大会通过的职权回购授权，允许回购的股份总数为84,120,311股，截至目前公司已合计回购1,080,000股，占该授权所涉已发行股份总数的1.2839%。
公司在公告中确认，所有回购股份事宜均依据香港联合交易所证券上市规则及相关法律法规的规定进行。公告由公司秘书高海恩签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.